NCT02866682View on ClinicalTrials.gov

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Renal Transplant Rejection
Interventions
DRUG

Prograf

Brand Drug for the duration of the study.

DRUG

Tacrolimus

Generic

Trial Locations (1)

90024

UCLA Kidney Transplant Research, Los Angeles

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

University of California, Los Angeles

OTHER

NCT02866682 - Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter